Tumor-suppressing viruses, genes, and drugs : innovative cancer therapy approaches
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Hiroshi Maruta
- ناشر : San Diego : Academic Press
- چاپ و سال / کشور: 2002
- شابک / ISBN : 9780124762497
Description
Oncolytic Viruses: Virotherapy for Cancer Reovirus Therapy of Ras-Associated Cancers Oncolytic Herpes Simplex Virus (G207) Therapy: p53 and Its Targets Prospects for Tumor Suppressor Gene Therapy Cytoskeletal Tumor Suppressor Genes TGF- Signaling and Carcinogenesis RAS Binding Compounds Actin-Binding Drugs: MKT-077 and Chaetoglobosin K (CK) 329
Ch. 1. Oncolytic viruses: virotherapy for cancer --
Ch. 2. Reovirus therapy of Ras-associated cancers --
Ch. 3. Oncolytic herpes simplex virus (G207) therapy: from basic to clinical --
Ch. 4. p53 and its targets --
Ch. 5. Prospects for tumor suppressor gene therapy: RB as an example --
Ch. 6. CDK inhibitors: genes and drugs --
Ch. 7. CDK inhibitors: small molecular weight compounds --
Ch. 8. NF1 and other RAS-binding peptides --
Ch. 9. Cytoskeletal tumor suppressor genes --
Ch. 10. TGF-[beta] signaling and carcinogenesis --
Ch. 11. DAN gene --
Ch. 12. Design of hammerhead ribozymes and allosterically controllable maxizymes for cancer gene therapy --
Ch. 13. Inhibitors of angiogenesis --
Ch. 14. Geranylgeranylated RhoB mediates the apoptotic and antineoplastic effects of farnesyltransferase inhibitors: new insights into cancer cell suicide --
Ch. 15. RAS binding compounds --
Ch. 16. Actin-binding drugs: MKT-007 and chaetoglobosin K (CK) --
Ch. 17. Tyr kinase inhibitors as potential anticancer agents: EGF receptor and ABL kinases --
Ch. 18. Antagonists of Rho family GTPases: blocking PAKs, ACKs, and rock --
Ch. 19. Integrin antagonists as cancer therapeutics --
Ch. 20. Functional rescue of mutant p53 as a strategy to combat cancer
Ch. 2. Reovirus therapy of Ras-associated cancers --
Ch. 3. Oncolytic herpes simplex virus (G207) therapy: from basic to clinical --
Ch. 4. p53 and its targets --
Ch. 5. Prospects for tumor suppressor gene therapy: RB as an example --
Ch. 6. CDK inhibitors: genes and drugs --
Ch. 7. CDK inhibitors: small molecular weight compounds --
Ch. 8. NF1 and other RAS-binding peptides --
Ch. 9. Cytoskeletal tumor suppressor genes --
Ch. 10. TGF-[beta] signaling and carcinogenesis --
Ch. 11. DAN gene --
Ch. 12. Design of hammerhead ribozymes and allosterically controllable maxizymes for cancer gene therapy --
Ch. 13. Inhibitors of angiogenesis --
Ch. 14. Geranylgeranylated RhoB mediates the apoptotic and antineoplastic effects of farnesyltransferase inhibitors: new insights into cancer cell suicide --
Ch. 15. RAS binding compounds --
Ch. 16. Actin-binding drugs: MKT-007 and chaetoglobosin K (CK) --
Ch. 17. Tyr kinase inhibitors as potential anticancer agents: EGF receptor and ABL kinases --
Ch. 18. Antagonists of Rho family GTPases: blocking PAKs, ACKs, and rock --
Ch. 19. Integrin antagonists as cancer therapeutics --
Ch. 20. Functional rescue of mutant p53 as a strategy to combat cancer
